Oncology News and Research

RSS
Protein produced by soft-tissue sarcomas makes immune cells ‘go bad’

Protein produced by soft-tissue sarcomas makes immune cells ‘go bad’

Breast cancer trial results may not translate to real-world outcomes based on treatment discontinuation

Breast cancer trial results may not translate to real-world outcomes based on treatment discontinuation

International researchers win funding for Cancer Grand Challenge

International researchers win funding for Cancer Grand Challenge

Researchers identify a signature of three genes linked to positive response to blood cancer therapy

Researchers identify a signature of three genes linked to positive response to blood cancer therapy

Androgen receptor signaling affects response to targeted therapy in people with melanoma

Androgen receptor signaling affects response to targeted therapy in people with melanoma

Synexa Life Sciences Strengthens its Executive Team for Further Growth

Synexa Life Sciences Strengthens its Executive Team for Further Growth

Syrinx Bioanalytics Acquired by Synexa Life Sciences to Expand Scope of Bioanalysis

Syrinx Bioanalytics Acquired by Synexa Life Sciences to Expand Scope of Bioanalysis

Prostate cancer treatment guidelines need to be updated, research suggests

Prostate cancer treatment guidelines need to be updated, research suggests

Understanding how diet and the microbiome impact colorectal cancer rates

Understanding how diet and the microbiome impact colorectal cancer rates

Native Americans have to travel large distances to access radiation therapy, study shows

Native Americans have to travel large distances to access radiation therapy, study shows

Treatment with immunity-boosting protein enhances the function of CAR-T cells in fighting blood cancers

Treatment with immunity-boosting protein enhances the function of CAR-T cells in fighting blood cancers

AI tool allows clinicians to make optimal, personalized chemotherapy doses for patients

AI tool allows clinicians to make optimal, personalized chemotherapy doses for patients

Stress protein in fibroblasts appears to be an attractive cancer drug target

Stress protein in fibroblasts appears to be an attractive cancer drug target

Study reveals the benefits of using thalidomide in patients with severe arteriovenous malformations

Study reveals the benefits of using thalidomide in patients with severe arteriovenous malformations

Research reveals why many cancers are vulnerable to FDA-approved IDH1 inhibitors

Research reveals why many cancers are vulnerable to FDA-approved IDH1 inhibitors

Inhaled recombinant IL-15 tested in pet dogs with metastatic lung disease from osteosarcoma or melanoma

Inhaled recombinant IL-15 tested in pet dogs with metastatic lung disease from osteosarcoma or melanoma

Cryo-EM helps scientists to decipher the structure of a key part of RNA degradation machinery

Cryo-EM helps scientists to decipher the structure of a key part of RNA degradation machinery

Researchers reveal important factor behind cancer therapy resistance and a way to counter it

Researchers reveal important factor behind cancer therapy resistance and a way to counter it

Synthetic IL-9 receptor allows T cells to fight cancer without the need for chemo or radiation

Synthetic IL-9 receptor allows T cells to fight cancer without the need for chemo or radiation

Oral pill taken once a day improves outcomes of patients with myelofibrosis

Oral pill taken once a day improves outcomes of patients with myelofibrosis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.